Ticagrelor on the percutaneous coronary intervention in patients with the clopidogrel intermediate metabolic non-ST-segment elevation acute coronary syndrome

Objective To investigate ticagrelor on the percutaneous coronary intervention(PCI) in patients with the clopidogrel inter-mediate metabolic non-ST-segment elevation acute coronary syndrome(NSTE-ACS).Methods A retrospective study was performed on 97 cases of patients with NSTE-ACS(detected by CYP2C19 gene polymorphism detection) who undergoing PCI from December 2015 to September 2016.Patients were randomly divided into Group A(n=50) and Group B(n=47).Patients in Group A received conventional dual antiplatelet therapy after PCI,aspirin 100 mg+ clopidogrel 75 mg,once per day orally;patients in Group B received aspirin 100 mg + ticagrelor 90 mg,once per day orally. The incidence of platelet aggregation and major adverse cardiac events (MACE) in the two groups were compared in 12 months of telephone,outpatient or in-patient follow-up.Results The maximum ag-gregation rate of platelets in Group A and Group B were(58.78% ± 8.46%) and(38.84% ± 17.00%),which had statistically sig-nificant difference(P 0.05).Conclusion The effect of ticagrelor on inhibitting platelet function in patients with clopidogrel intermediate metabolic NSTE-ACS is more effective,which can take place of clopidogrel.